.jpg "Agenus (AGEN) Receives a Buy from B.Riley FBR")
In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Agenus (AGEN), with a price target of $8.00. The company’s shares closed last Thursday at $4.03.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 15.5% and a 48.6% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
Currently, the analyst consensus on Agenus is a Moderate Buy with an average price target of $8.00.
See today’s analyst top recommended stocks >>
Based on Agenus’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $26.95 million and GAAP net loss of $47.48 million. In comparison, last year the company earned revenue of $15.72 million and had a GAAP net loss of $50.63 million.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AGEN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
Read More on AGEN:
